However, despite a high response rate of 60% in Alk-rearranged NSCLC, resistance to therapy based on Alk inhibition was shown to develop typically within one to 2 years (Friboulet et al., 2014; Mizuta et al., 2021). This evidence concerns the gene ALK and non-small cell lung carcinoma.